See today's BioWorld Asia
To read the full story, subscribe or sign in.

Rapt licenses FLX-475 to Hanmi in deal worth up to $118M

Dec. 10, 2019
By Jihyun Kim
HONG KONG – Rapt Therapeutics Inc., of San Francisco, and Seoul, South Korea-based Hanmi Pharmaceutical Co. Ltd. entered a license agreement for Rapt’s FLX-475 in Asia. FLX-475 is an oral, small-molecule CCR4 antagonist for cancer treatment. 
BioWorld Asia Deals and M&A Cancer Asia-Pacific